Image de couverture de livre

Effects of glucagon‐like PEPTIDE‐1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META‐analysis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Andrea Pasta, Antonio Facciorusso, Maria Corina Plaz Torres, Edoardo G. Giannini, Rodolfo Sacco
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	European Journal of Clinical Investigation
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes
par: Yu‐Ting Yu, et autres
Publié: (2026)

Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
par: Andrea Saglietto, et autres
Publié: (2024)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
par: Hirotaka Watada
Publié: (2024)

The glucagon‐like peptide‐1 receptor agonist semaglutide in diabetic kidney disease: A new kid on the block to afford maximal kidney protection
par: Panagiotis I. Georgianos, et autres
Publié: (2024)

Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
par: Mehmet Kanbay, et autres
Publié: (2024)

The impact of immature granulocytes on the outcome of patients with decompensated cirrhosis
par: Magdalini Adamantou, et autres
Publié: (2025)

GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study
par: Anastasios Tentolouris, et autres
Publié: (2025)

Commentary on “Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes ( post hoc analysis of RECAP study)”
par: Yu Zhang, et autres
Publié: (2025)

The efficacy and safety of EGFR‐TKI in recurrent/metastatic nasopharyngeal carcinoma patients: A systematic review and meta‐analysis
par: Zeqi An, et autres
Publié: (2024)

Incretin system and glucagon secretion in patients with chronic pancreatitis
par: Gea Ciccarelli, et autres
Publié: (2025)

The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial
par: Andrea Pasta, et autres
Publié: (2025)

Smoking and diabetic nephropathy: An updated systematic review and meta‐analysis
par: Haihui Zhu, et autres
Publié: (2024)

Association between diabetic peripheral neuropathy and lower limb muscle strength in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
par: Yuki Nakashima, et autres
Publié: (2025)

Prevalence, incidence, and risk factors of diabetic retinopathy and macular edema in patients with early and late‐onset type 2 diabetes mellitus
par: Ching‐Kit Tsui, et autres
Publié: (2025)

Metabolic dysfunction‐associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria – NAGALA study
par: Kimiko Sakai, et autres
Publié: (2024)

Commentary on “Prevalence, incidence, and risk factors of diabetic retinopathy and macular edema in patients with early and late‐onset type 2 diabetes mellitus”
par: Fatemeh Rasulpur, et autres
Publié: (2025)

Adiponectin as a biomarker in liver cirrhosis—A systematic review and meta‐analysis
par: Abdulrahman Ismaiel, et autres
Publié: (2024)

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice
par: Osamu Kikuchi, et autres
Publié: (2024)

Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes
par: Hiroyuki Ito, et autres
Publié: (2025)

Regulation of glucose and energy metabolism through actions of glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide
par: Yasuo Zenimaru, et autres
Publié: (2024)

Branched‐chain amino acids and all‐cause mortality in patients with liver cirrhosis, and the onset of diabetes in liver transplant recipients
par: Yakun Li, et autres
Publié: (2025)

Angiopoietin‐like 4 is a potential biomarker for diabetic kidney disease in type 2 diabetes patients
par: Yan Wang, et autres
Publié: (2024)

Cardiovascular and kidney benefits of GLP ‐1 receptor agonists across large randomized placebo‐controlled trials
par: Satoshi Yoshiji, et autres
Publié: (2025)

Comment on “Branched‐chain amino acids and all‐cause mortality in patients with liver cirrhosis, and the onset of diabetes in liver transplant recipients”
par: Rachana Mehta, et autres
Publié: (2025)

Response to the letter to the editor regarding “Association between diabetic peripheral neuropathy and lower limb muscle strength in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis”
par: Yuki Nakashima, et autres
Publié: (2026)

Response to the comment on ‘Branched‐chain amino acids and all‐cause mortality in patients with liver cirrhosis, and the onset of diabetes in liver transplant recipients’
par: Yakun Li, et autres
Publié: (2025)

Postpartum life interventions to prevent type 2 diabetes in women with gestational diabetes: A systematic review and meta‐analysis
par: Yu Wang, et autres
Publié: (2024)

Non‐linear relationship between liver fibrosis and femoral neck bone mineral density in metabolic dysfunction‐associated fatty liver disease patients with type 2 diabetes mellitus
par: Jie Tao, et autres
Publié: (2025)

Letter to the Editor in response to the article “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes”
par: Akash Suthar, et autres
Publié: (2025)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
par: Fumika Kamitani, et autres
Publié: (2024)

Efficacy and safety of premixed versus basal‐bolus regimens as intensification of insulin therapy in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis of randomized clinical trials
par: Mohsen Dehghani, et autres
Publié: (2025)

A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients
par: Tingting Li, et autres
Publié: (2025)

Epac2 activation mediates glucagon‐induced glucogenesis in primary rat hepatocytes
par: Yusuke Shiozaki‐Takagi, et autres
Publié: (2024)

Commentary on “Intra‐islet α‐cell Gs signaling promotes glucagon release”
par: Tadahiro Kitamura
Publié: (2024)

Risk factors and prediction score for new‐onset diabetes mellitus after liver transplantation
par: Ruiping Bai, et autres
Publié: (2024)

Low‐carbohydrate diets in East Asians with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
par: Junya Hironaka, et autres
Publié: (2024)

Association between obstructive sleep apnea syndrome and type1/type2 diabetes mellitus: A systematic review and meta‐analysis
par: Huiling Huang, et autres
Publié: (2024)

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
par: Jae Hyun Bae, et autres
Publié: (2024)

Eating behaviors and incidence of type 2 diabetes in Japanese people: The population‐based Panasonic cohort study 15
par: Ema Toyokuni, et autres
Publié: (2024)

Letter to the Editor in response to the article ‘Prevalence and risk factors of sarcopenia in Asian adults with type 2 diabetes: A systematic review and meta‐analysis’
par: Mina He
Publié: (2026)